期刊
CLINICAL LYMPHOMA & MYELOMA
卷 9, 期 2, 页码 151-153出版社
CIG MEDIA GROUP, LP
DOI: 10.3816/CLM.2009.n.036
关键词
Dermatomal rash; Herpes zoster; Herpetic neuralgia; Infectious complications
类别
资金
- [MSMT LC 06027]
- [MSM 0021622434]
- [16A MZCO]
- [NR/9225]
Background: Varicella-zoster virus (VZV) reactivation is a common complication in patients with multiple myeloma (MM) treated with bortezomib, with an incidence rate of 10%-60%. The aim of our study was to analyze the effect of acyclovir prophylaxis in this patient population. Patients and Methods: We studied 98 consecutive patients with relapsed MM treated with bortezomib. Bortezomib 1.3 mg/m(2) was given on days 1, 4, 8, and 11 of a 21-day cycle. At first, patients did not receive any VZV prophylaxis, but because of the high incidence of VZV reactivation, VZV prophylaxis with acyclovir was implemented subsequently. Results: A total of 11 patients treated with bortezomib did not have any VZV prophylaxis, and 4 of these 11 patients (36%) developed VZV reactivation in the form of herpes zoster. No VZV reactivations were observed in the 32 patients who received acyclovir 400 mg 3 times daily or the 55 patients who received acyclovir in a dose reduced to 400 mg once daily during bortezomib treatment. Conclusion: Varicella-zoster virus reactivation is a common and serious adverse effect of bortezomib treatment. Acyclovir 400 mg once daily is sufficient to protect from VZV reactivation in patients with MM treated with bortezomib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据